| Phase 12 trials |
|
Phase 1
|
NCT07057674 |
Apr 2025 → Feb 2026 overdue |
obesity disorder |
Jiangsu Hansoh Pharmaceutical Co., Ltd. |
Recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT05116410 |
Nov 2021 → Oct 2022 |
type 2 diabetes mellitus |
Jiangsu Hansoh Pharmaceutical Co., Ltd. |
Unknown
|
No outcome recorded
|
| Phase 25 trials |
|
Phase 2
|
NCT07685808 |
Jul 2026 → Jan 2028 expected |
obesity disorder |
Regeneron Pharmaceuticals |
Not yet recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT07431086 |
Mar → Nov 2026 expected |
obesity disorder |
Regeneron Pharmaceuticals |
Active not recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT06901648 |
Feb 2024 → Mar 2025 |
type 2 diabetes mellitus |
Jiangsu Hansoh Pharmaceutical Co., Ltd. |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT06118021 |
Oct 2023 → Aug 2024 |
— |
Jiangsu Hansoh Pharmaceutical Co., Ltd. |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT06118008 |
May 2023 → Jan 2024 |
type 2 diabetes mellitus |
Jiangsu Hansoh Pharmaceutical Co., Ltd. |
Completed
|
No outcome recorded
|
| Phase 33 trials |
|
Phase 3
|
NCT07156539 |
Sep 2025 → Mar 2027 expected |
type 2 diabetes mellitus |
Jiangsu Hansoh Pharmaceutical Co., Ltd. |
Not yet recruiting
|
No outcome recorded
|
|
Phase 3
|
NCT07156500 |
Sep 2025 → Mar 2027 expected |
type 2 diabetes mellitus |
Jiangsu Hansoh Pharmaceutical Co., Ltd. |
Not yet recruiting
|
No outcome recorded
|
|
Phase 3
|
NCT06839664 |
Nov 2024 → Jan 2026 |
obesity disorder |
Jiangsu Hansoh Pharmaceutical Co., Ltd. |
Completed
|
No outcome recorded
|